Newport Trust Co Has $210.43 Million Position in Allergan plc (NYSE:AGN)

Newport Trust Co cut its position in Allergan plc (NYSE:AGN) by 1.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,250,381 shares of the company’s stock after selling 18,721 shares during the quarter. Allergan comprises 0.6% of Newport Trust Co’s portfolio, making the stock its 18th biggest holding. Newport Trust Co’s holdings in Allergan were worth $210,427,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Prestige Wealth Management Group LLC acquired a new position in shares of Allergan in the 2nd quarter valued at approximately $25,000. Old North State Trust LLC raised its position in shares of Allergan by 172.4% in the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock valued at $27,000 after buying an additional 100 shares in the last quarter. Motco acquired a new position in shares of Allergan in the 2nd quarter valued at approximately $29,000. HM Payson & Co. acquired a new position in shares of Allergan in the 2nd quarter valued at approximately $29,000. Finally, Reilly Financial Advisors LLC raised its position in shares of Allergan by 129.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock valued at $29,000 after buying an additional 97 shares in the last quarter. Institutional investors own 80.70% of the company’s stock.

AGN stock traded up $2.60 during trading on Friday, reaching $181.28. 2,339,664 shares of the company were exchanged, compared to its average volume of 3,255,166. The company has a 50-day moving average of $171.62 and a two-hundred day moving average of $155.71. The company has a market capitalization of $58.54 billion, a price-to-earnings ratio of 10.86, a P/E/G ratio of 2.11 and a beta of 1.66. Allergan plc has a twelve month low of $114.27 and a twelve month high of $181.45. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.67 and a quick ratio of 0.91.

Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, November 5th. The company reported $4.25 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $4.25. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $4.25 EPS. On average, analysts forecast that Allergan plc will post 16.7 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Wednesday, November 13th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Tuesday, November 12th. Allergan’s payout ratio is 17.74%.

Several equities analysts have recently commented on AGN shares. TheStreet upgraded shares of Allergan from a “d+” rating to a “c” rating in a research report on Friday, July 12th. Barclays boosted their target price on shares of Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 7th. ValuEngine cut shares of Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein cut shares of Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 target price for the company. in a research report on Tuesday, July 16th. Finally, Guggenheim cut shares of Allergan from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the company’s stock. Allergan presently has a consensus rating of “Hold” and a consensus price target of $175.16.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Recommended Story: How can you know how many shares are floating?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.